Lytix Biopharma and KAEL–GemVax Announce First Patient Treated in Clinical Trial to Combine LTX-315 and GV1001 Cancer Vaccine Immunotherapy

OSLO & SEOUL, South Korea--(BUSINESS WIRE)--The Norwegian biopharmaceutical company Lytix Biopharma and the Korean biotechnology company KAEL-GemVax announced today the successful first treatment in the study of a combination of LTX-315 and GV1001 as anti-cancer vaccine therapy.

Back to news